BTAI

Insider Trades

Name	Value	Action	Price	Current Price
Mehta VimalDirector, Officer: CEO And President $21k19.4k shares SellMay 20, 2026 $1.09 --
Rodriguez JavierSee Remarks $7.1k6.6k shares SellMay 20, 2026 $1.08 --
Steinhart Richard IChief Financial Officer $7.4k6.8k shares SellMay 20, 2026 $1.09 --
Yocca FrankChief Scientific Officer $7.4k6.8k shares SellMay 20, 2026 $1.09 --

News

zacks.comWhat Makes BioXcel Therapeutics (BTAI) a New Buy Stockzacks.comJun 2

globenewswire.comBioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meetingglobenewswire.comMay 28

zacks.comBioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimateszacks.comMay 15

globenewswire.comBioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Resultsglobenewswire.comMay 15

zacks.comBioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?zacks.comMay 4

Trade BTAI

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder. Beyond its current commercial use, BXCL501 is also undergoing further clinical investigation. Studies are underway to assess its efficacy for agitation in individuals with Alzheimer's disease, as an add-on therapy for major depressive disorder, and for use in community settings to address agitation linked to bipolar disorders and schizophrenia. Furthermore, BioXcel is advancing BXCL502, a candidate therapy targeting chronic agitation prevalent in dementia patients. Another key pipeline asset is BXCL701, an orally administered systemic innate immunity activator currently under investigation. This compound shows promise for treating aggressive prostate cancer and advanced solid tumors that have either become resistant to checkpoint inhibitors or have not yet received such treatment. Established in 2017, the company maintains its headquarters in New Haven, Connecticut.

CEO: Vimal D. Mehta
IPO Date: Mar 8, 2018

Market Data

Open: $1.20
High: $1.23
Low: $1.18
Volume: 416.4K
Avg Volume: 811.1K
52W High: $8.08
52W Low: $1.01

Valuation

Market Cap: $37M
Enterprise Value: $120M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-58M
Revenue: $642k
Net Income: $-70M
Cash: $28M
Debt: $110M

Events

EarningsAug 11

EPS est. -0.4225